Hyalohyphomycoses (Hyaline Moulds)

  • Harrys A. Torres
  • Dimitrios P. Kontoyiannis


The hyalohyphomycoses, or hyaline moulds, are human ­infections caused by soil-dwelling and plant saprophytic moulds [1]. Hyalohyphomycosis encompasses a loose artificial classification system since it does not refer to a specific taxonomic classification [2]. Agents of hyalohyphomycosis include non-melanin-producing, nondematiaceous moulds, which typically appear on histopathologic sections as colorless, hyaline, or light-colored septate hyphae [3]. These hyphae are either branched or unbranched, and occasionally they are toruloid [1, 3, 4]. Important human pathogens included in this group are Aspergillus, Penicillium, Fusarium, Scopulariopsis, Pseudallescheria, Scedosporium, Acremonium, Paecilomyces, and Trichoderma species (Table 1) [1, 3, 5–8].


Hematopoietic Stem Cell Transplant Fusarium Species Solid Organ Transplant Recipient Trichoderma Species Hematopoietic Stem Cell Transplant Recipient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Ajello L. Hyalohyphomycosis and phaeohyphomycosis: two global disease entities of public health importance. Eur J Epidemiol. 1986;2:243–51.PubMedGoogle Scholar
  2. 2.
    Rippon J. Hyalohyphomycosis, pythiosis, miscellaneous and rare mycoses, and algoses. In: Rippon JW, editor. Medical Mycology. 3rd ed. Philadelphia: W. B. Saunders Company; 1988. p. 714–45.Google Scholar
  3. 3.
    Anaissie EJ, Bodey GP, Rinaldi MG. Emerging fungal pathogens. Eur J Clin Microbiol Infect Dis. 1989;8:323–30.PubMedGoogle Scholar
  4. 4.
    Liu K, Howell DN, Perfect JR, Schell WA. Morphologic criteria for the preliminary identification of Fusarium, Paecilomyces, and Acremonium species by histopathology. Am J Clin Pathol. 1998;109:45–54.PubMedGoogle Scholar
  5. 5.
    Alanio A, Brethon B. Feuilhade de Chauvin M, et al. Invasive pulmonary infection due to Trichoderma longibrachiatum mimicking invasive Aspergillosis in a neutropenic patient successfully treated with voriconazole combined with caspofungin Clin Infect Dis. 2008;46:e116–8.Google Scholar
  6. 6.
    Chamilos G, Kontoyiannis DP. Voriconazole-resistant disseminated Paecilomyces variotii infection in a neutropenic patient with leukaemia on voriconazole prophylaxis. J Infect. 2005;51:e225–8.PubMedGoogle Scholar
  7. 7.
    Mattei D, Mordini N, Lo Nigro C, et al. Successful treatment of Acremonium fungemia with voriconazole. Mycoses. 2003;46:511–4.PubMedGoogle Scholar
  8. 8.
    Schinabeck MK, Ghannoum MA. Human hyalohyphomycoses: a review of human infections due to Acremonium spp., Paecilomyces spp., Penicillium spp., and Scopulariopsis spp. J Chemother. 2003;15 Suppl 2:5–15.PubMedGoogle Scholar
  9. 9.
    Young NA, Kwon-Chung KJ, Kubota TT, Jennings AE, Fisher RI. Disseminated infection by Fusarium moniliforme during treatment for malignant lymphoma. J Clin Microbiol. 1978;7:589–94.PubMedGoogle Scholar
  10. 10.
    Anaissie E, Kantarjian H, Ro J, et al. The emerging role of Fusariuminfections in patients with cancer. Medicine (Baltimore). 1988;67:77–83.Google Scholar
  11. 11.
    Walsh TJ, Groll AH. Emerging fungal pathogens: evolving ­challenges to immunocompromised patients for the twenty-first century. Transpl Infect Dis. 1999;1:247–61.PubMedGoogle Scholar
  12. 12.
    Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years’ experience at a cancer center and implications for management. Blood. 1997;90:999–1008.PubMedGoogle Scholar
  13. 13.
    Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002;34:909–17.PubMedGoogle Scholar
  14. 14.
    Girmenia C, Pagano L, Corvatta L, Mele L, del Favero A, Martino P. The epidemiology of fusariosis in patients with haematological diseases. Gimema Infection Programme. Br J Haematol. 2000;111:272–6.PubMedGoogle Scholar
  15. 15.
    Torres HA, Raad II, Kontoyiannis DP. Infections caused by Fusarium species. J Chemother. 2003;15 Suppl 2:28–35.PubMedGoogle Scholar
  16. 16.
    Guarro J, Gene J. Opportunistic fusarial infections in humans. Eur J Clin Microbiol Infect Dis. 1995;14:741–54.PubMedGoogle Scholar
  17. 17.
    Nir-Paz R, Strahilevitz J, Shapiro M, et al. Clinical and epidemiological aspects of infections caused by Fusarium species: a collaborative study from Israel. J Clin Microbiol. 2004;42:3456–61.PubMedGoogle Scholar
  18. 18.
    Azor M, Gene J, Cano J, et al. In vitro antifungal susceptibility and molecular characterization of clinical isolates of Fusarium verticillioides (F. moniliforme) and Fusarium thapsinum. Antimicrob Agents Chemother. 2008;52:2228–31.PubMedGoogle Scholar
  19. 19.
    Campos S, Caramori M, Teixeira R, et al. Bacterial and fungal pneumonias after lung transplantation. Transplant Proc. 2008;40:822–4.PubMedGoogle Scholar
  20. 20.
    Trabasso P, Vigorito A, De Souza C, et al. Invasive fungal infection in hematopoietic stem cell transplant recipients at a Brazilian university hospital. In: Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy 2001 Chicago, IL; 2001.Google Scholar
  21. 21.
    Nucci M, Marr KA, Queiroz-Telles F, et al. Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2004;38:1237–42.PubMedGoogle Scholar
  22. 22.
    Fridkin SK, Jarvis WR. Epidemiology of nosocomial fungal infections. Clin Microbiol Rev. 1996;9:499–511.PubMedGoogle Scholar
  23. 23.
    Squier C, Yu VL, Stout JE. Waterborne nosocomial infections. Curr Infect Dis Rep. 2000;2:490–6.PubMedGoogle Scholar
  24. 24.
    Anaissie EJ, Kuchar RT, Rex JH, et al. Fusariosis associated with pathogenic fusarium species colonization of a hospital water system: a new paradigm for the epidemiology of opportunistic mold infections. Clin Infect Dis. 2001;33:1871–8.PubMedGoogle Scholar
  25. 25.
    Kivivuori SM, Hovi L, Vettenranta K, Saarinen-Pihkala UM. Invasive fusariosis in two transplanted children. Eur J Pediatr. 2004;163:692–3.PubMedGoogle Scholar
  26. 26.
    Raad I, Tarrand J, Hanna H, et al. Epidemiology, molecular mycology, and environmental sources of Fusarium infection in patients with cancer. Infect Control Hosp Epidemiol. 2002;23:532–7.PubMedGoogle Scholar
  27. 27.
    Alastruey-Izquierdo A, Cuenca-Estrella M, Monzon A, Mellado E, Rodriguez-Tudela JL. Antifungal susceptibility profile of clinical Fusarium spp. isolates identified by molecular methods. J Antimicrob Chemother. 2008;61:805–9.PubMedGoogle Scholar
  28. 28.
    Tortorano AM, Prigitano A, Dho G, et al. Species distribution and in vitro antifungal susceptibility patterns of 75 clinical isolates of Fusarium spp. from northern Italy. Antimicrob Agents Chemother. 2008;52:2683–5.PubMedGoogle Scholar
  29. 29.
    Summerbell RC, Schroers HJ. Analysis of phylogenetic relationship of Cylindrocarpon lichenicola and Acremonium falciforme to the Fusarium solani species complex and a review of similarities in the spectrum of opportunistic infections caused by these fungi. J Clin Microbiol. 2002;40:2866–75.PubMedGoogle Scholar
  30. 30.
    Guarro J, Rubio C, Gene J, et al. Case of keratitis caused by an uncommon Fusarium species. J Clin Microbiol. 2003;41:5823–6.PubMedGoogle Scholar
  31. 31.
    Cordoba S, Rodero L, Vivot W, Abrantes R, Davel G, Vitale RG. In vitro interactions of antifungal agents against clinical isolates of Fusarium spp. Int J Antimicrob Agents. 2008;31:171–4.PubMedGoogle Scholar
  32. 32.
    Mayayo E, Pujol I, Guarro J. Experimental pathogenicity of four opportunist Fusarium species in a murine model. J Med Microbiol. 1999;48:363–6.PubMedGoogle Scholar
  33. 33.
    Nelson PE, Dignani MC, Anaissie EJ. Taxonomy, biology, and clinical aspects of Fusarium species. Clin Microbiol Rev. 1994;7:479–504.PubMedGoogle Scholar
  34. 34.
    Ponton J, Ruchel R, Clemons KV, et al. Emerging pathogens. Med Mycol. 2000;38 Suppl 1:225–36.PubMedGoogle Scholar
  35. 35.
    Etzel RA. Mycotoxins. JAMA. 2002;287:425–7.PubMedGoogle Scholar
  36. 36.
    Groll AH, Walsh TJ. Uncommon opportunistic fungi: new nosocomial threats. Clin Microbiol Infect. 2001;7 Suppl 2:8–24.PubMedGoogle Scholar
  37. 37.
    Gong YY, Torres-Sanchez L, Lopez-Carrillo L, et al. Association between tortilla consumption and human urinary fumonisin B1 levels in a Mexican population. Cancer Epidemiol Biomark Prev. 2008;17:688–94.Google Scholar
  38. 38.
    Pitt JI. Toxigenic fungi: which are important? Med Mycol. 2000;38 Suppl 1:17–22.PubMedGoogle Scholar
  39. 39.
    Campo M, Lewis R, Kontoyiannis DP. Invasive fusariosis in patients with hematologic malignancy at MD Anderson Cancer Center: The last decade. In: Abstracts of the 47th Annual Meeting of the Infectious Diseases Society of America 2009; Philadelphia, Pennsylvania; 2009.Google Scholar
  40. 40.
    Girmenia C, Iori AP, Boecklin F, et al. Fusarium infections in patients with severe aplastic anemia: Review and implications for management. Haematologica. 1999;84:114–8.PubMedGoogle Scholar
  41. 41.
    Torres HA, Bodey GP, Rolston KV, Kantarjian HM, Raad II, Kontoyiannis DP. Infections in patients with aplastic anemia: experience at a tertiary care cancer center. Cancer. 2003;98:86–93.PubMedGoogle Scholar
  42. 42.
    Sagnelli C, Fumagalli L, Prigitano A, Baccari P, Magnani P, Lazzarin A. Successful voriconazole therapy of disseminated Fusarium verticillioides infection in an immunocompromised patient receiving chemotherapy. J Antimicrob Chemother. 2006;57:796–8.PubMedGoogle Scholar
  43. 43.
    Mansoory D, Roozbahany NA, Mazinany H, Samimagam A. Chronic Fusarium infection in an adult patient with undiagnosed chronic granulomatous disease. Clin Infect Dis. 2003;37:e107–8.PubMedGoogle Scholar
  44. 44.
    Winn RM, Gil-Lamaignere C, Roilides E, et al. Effects of interleukin-15 on antifungal responses of human polymorphonuclear leukocytes against Fusarium spp. and Scedosporium spp. Cytokine. 2005;31:1–8.PubMedGoogle Scholar
  45. 45.
    Lamaris GA, Chamilos G, Lewis RE, Kontoyiannis DP. Virulence studies of Scedosporium and Fusarium species in Drosophila melanogaster. J Infect Dis. 2007;196:1860–4.PubMedGoogle Scholar
  46. 46.
    Lionakis MS, Lewis RE, May GS, et al. Toll-deficient Drosophila flies as a fast, high-throughput model for the study of antifungal drug efficacy against invasive aspergillosis and Aspergillus virulence. J Infect Dis. 2005;191:1188–95.PubMedGoogle Scholar
  47. 47.
    Goldblum D, Frueh BE, Zimmerli S, Bohnke M. Treatment of postkeratitis Fusarium endophthalmitis with amphotericin B lipid complex. Cornea. 2000;19:853–6.PubMedGoogle Scholar
  48. 48.
    Chang DC, Grant GB, O’Donnell K, et al. Multistate outbreak of Fusarium keratitis associated with use of a contact lens solution. JAMA. 2006;296:953–63.PubMedGoogle Scholar
  49. 49.
    Girmenia C, Arcese W, Micozzi A, Martino P, Bianco P, Morace G. Onychomycosis as a possible origin of disseminated Fusarium solani infection in a patient with severe aplastic anemia. Clin Infect Dis. 1992;14:1167.PubMedGoogle Scholar
  50. 50.
    Kontoyiannis D. Mycetoma. In: Goldman L BJ, eds., ed. Cecil Textbook of Medicine. Philadelphia: W. B. Saunders; 2004:2067–8.Google Scholar
  51. 51.
    Wheeler MS, McGinnis MR, Schell WA, Walker DH. Fusarium infection in burned patients. Am J Clin Pathol. 1981;75:304–11.PubMedGoogle Scholar
  52. 52.
    Assaf C, Goerdt S, Seibold M, Orfanos C. Clinical picture. Cutaneous hyalohyphomycosis. Lancet. 2000;356:1185.PubMedGoogle Scholar
  53. 53.
    Marom EM, Holmes AM, Bruzzi JF, Truong MT, O’Sullivan PJ, Kontoyiannis DP. Imaging of pulmonary fusariosis in patients with hematologic malignancies. AJR Am J Roentgenol. 2008;190:1605–9.PubMedGoogle Scholar
  54. 54.
    Merz WG, Karp JE, Hoagland M, Jett-Goheen M, Junkins JM, Hood AF. Diagnosis and successful treatment of fusariosis in the compromised host. J Infect Dis. 1988;158:1046–55.PubMedGoogle Scholar
  55. 55.
    Richardson SE, Bannatyne RM, Summerbell RC, Milliken J, Gold R, Weitzman SS. Disseminated fusarial infection in the immunocompromised host. Rev Infect Dis. 1988;10:1171–81.PubMedGoogle Scholar
  56. 56.
    Minor Jr RL, Pfaller MA, Gingrich RD, Burns LJ. Disseminated Fusarium infections in patients following bone marrow transplantation. Bone Marrow Transplant. 1989;4:653–8.PubMedGoogle Scholar
  57. 57.
    el-Ani AS. Disseminated infection caused by Fusarium solani in a patient with aplastic anemia. NY State J Med. 1990;90:609–10.Google Scholar
  58. 58.
    Fang CT, Chang SC, Tang IL, et al. Fusarium solani fungemia in a bone marrow transplant recipient. J Formos Med Assoc. 1997;96:129–33.PubMedGoogle Scholar
  59. 59.
    Segal BH, Walsh TJ, Liu JM, Wilson JD, Kwon-Chung KJ. Invasive infection with Fusarium chlamydosporum in a patient with aplastic anemia. J Clin Microbiol. 1998;36:1772–6.PubMedGoogle Scholar
  60. 60.
    Mattiuzzi GN, Kantarjian H, O’Brien S, et al. Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy. Cancer. 2004;100:568–73.PubMedGoogle Scholar
  61. 61.
    Mattiuzzi GN, Alvarado G, Giles FJ, et al. Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother. 2006;50:143–7.PubMedGoogle Scholar
  62. 62.
    Cho CT, Vats TS, Lowman JT, Brandsberg JW, Tosh FE. Fusarium solani infection during treatment for acute leukemia. J Pediatr. 1973;83:1028–31.PubMedGoogle Scholar
  63. 63.
    Bodey GP, Boktour M, Mays S, et al. Skin lesions associated with Fusarium infection. J Am Acad Dermatol. 2002;47:659–66.PubMedGoogle Scholar
  64. 64.
    Nucci M, Anaissie E. Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management. Clin Infect Dis. 2002;35:909–20.PubMedGoogle Scholar
  65. 65.
    Patel R, Paya CV. Infections in solid-organ transplant recipients. Clin Microbiol Rev. 1997;10:86–124.PubMedGoogle Scholar
  66. 66.
    Sampathkumar P, Paya CV. Fusarium infection after solid-organ transplantation. Clin Infect Dis. 2001;32:1237–40.PubMedGoogle Scholar
  67. 67.
    Lodato F, Tame MR, Montagnani M, et al. Systemic fungemia and hepatic localizations of Fusarium solani in a liver transplanted patient: an emerging fungal agent. Liver Transplant. 2006;12:1711–4.Google Scholar
  68. 68.
    Anandi V, Vishwanathan P, Sasikala S, Rangarajan M, Subramaniyan CS, Chidambaram N. Fusarium solani breast abscess. Indian J Med Microbiol. 2005;23:198–9.PubMedGoogle Scholar
  69. 69.
    Walsh TJ, Francesconi A, Kasai M, Chanock SJ. PCR and single-strand conformational polymorphism for recognition of medically important opportunistic fungi. J Clin Microbiol. 1995;33:3216–20.PubMedGoogle Scholar
  70. 70.
    Hennequin C, Abachin E, Symoens F, et al. Identification of Fusarium species involved in human infections by 28S rRNA gene sequencing. J Clin Microbiol. 1999;37:3586–9.PubMedGoogle Scholar
  71. 71.
    Macedo DP, Neves RP, Fontan J, Souza-Motta CM, Lima D. A case of invasive rhinosinusitis by Fusarium verticillioides (Saccardo) Nirenberg in an apparently immunocompetent patient. Med Mycol. 2008;46:499–503.PubMedGoogle Scholar
  72. 72.
    Hayden RT, Isotalo PA, Parrett T, et al. In situ hybridization for the differentiation of Aspergillus, Fusarium, and Pseudallescheria species in tissue section. Diagn Mol Pathol. 2003;12:21–6.PubMedGoogle Scholar
  73. 73.
    Kontoyiannis DP, Sumoza D, Tarrand J, Bodey GP, Storey R, Raad II. Significance of aspergillemia in patients with cancer: a 10-year study. Clin Infect Dis. 2000;31:188–9.PubMedGoogle Scholar
  74. 74.
    Rex JH, Pfaller MA, Walsh TJ, et al. Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev. 2001;14:643–58.PubMedGoogle Scholar
  75. 75.
    Capilla J, Ortoneda M, Pastor FJ, Guarro J. In vitro antifungal activities of the new triazole UR-9825 against clinically important filamentous fungi. Antimicrob Agents Chemother. 2001;45:2635–7.PubMedGoogle Scholar
  76. 76.
    Kontoyiannis DP, Lewis RE. Antifungal drug resistance of ­pathogenic fungi. Lancet. 2002;359:1135–44.PubMedGoogle Scholar
  77. 77.
    Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi: Approved Standard, 2nd ed. M38-A2. In: Clinical and Laboratory Standards Institute Wayne, PA, USA; 2008.Google Scholar
  78. 78.
    Speeleveld E, Gordts B, Van Landuyt HW, De Vroey C, Raes-Wuytack C. Susceptibility of clinical isolates of Fusarium to antifungal drugs. Mycoses. 1996;39:37–40.PubMedGoogle Scholar
  79. 79.
    Marco F, Pfaller MA, Messer SA, Jones RN. In vitro activity of a new triazole antifungal agent, Sch 56592, against clinical isolates of filamentous fungi. Mycopathologia. 1998;141:73–7.PubMedGoogle Scholar
  80. 80.
    Li RK, Rinaldi MG. In vitro antifungal activity of nikkomycin Z in combination with fluconazole or itraconazole. Antimicrob Agents Chemother. 1999;43:1401–5.PubMedGoogle Scholar
  81. 81.
    Arikan S, Lozano-Chiu M, Paetznick V, Rex JH. In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrob Agents Chemother. 2001;45:327–30.PubMedGoogle Scholar
  82. 82.
    Johnson EM, Szekely A, Warnock DW. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J Antimicrob Chemother. 1998;42:741–5.PubMedGoogle Scholar
  83. 83.
    Arikan S, Lozano-Chiu M, Paetznick V, Nangia S, Rex JH. Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species. J Clin Microbiol. 1999;37:3946–51.PubMedGoogle Scholar
  84. 84.
    Pfaller MA, Messer SA, Hollis RJ, Jones RN. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother. 2002;46:1032–7.PubMedGoogle Scholar
  85. 85.
    Espinel-Ingroff A, Boyle K, Sheehan DJ. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia. 2001;150:101–15.PubMedGoogle Scholar
  86. 86.
    Paphitou NI, Ostrosky-Zeichner L, Paetznick VL, Rodriguez JR, Chen E, Rex JH. In vitro activities of investigational triazoles against Fusarium species: effects of inoculum size and incubation time on broth microdilution susceptibility test results. Antimicrob Agents Chemother. 2002;46:3298–300.PubMedGoogle Scholar
  87. 87.
    Minassian B, Huczko E, Washo T, Bonner D, Fung-Tomc J. In vitro activity of ravuconazole against Zygomycetes, Scedosporium and Fusarium isolates. Clin Microbiol Infect. 2003;9:1250–2.PubMedGoogle Scholar
  88. 88.
    Espinel-Ingroff A, Johnson E, Hockey H, Troke P. Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole Phase III clinical studies. J Antimicrob Chemother. 2008;61:616–20.PubMedGoogle Scholar
  89. 89.
    Roilides E, Lyman CA, Armstrong D, Stergiopoulou T, Petraitiene R, Walsh TJ. Deoxycholate amphotericin B and amphotericin B lipid complex exert additive antifungal activity in combination with pulmonary alveolar macrophages against Fusarium solani. Mycoses. 2006;49:109–13.PubMedGoogle Scholar
  90. 90.
    Guinea J, Pelaez T, Recio S, Torres-Narbona M, Bouza E. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1, 007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob Agents Chemother. 2008;52:1396–400.PubMedGoogle Scholar
  91. 91.
    Ortoneda M, Capilla J, Pastor FJ, Pujol I, Guarro J. Efficacy of liposomal amphotericin B in treatment of systemic murine fusariosis. Antimicrob Agents Chemother. 2002;46:2273–5.PubMedGoogle Scholar
  92. 92.
    Espinel-Ingroff A. Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743, 872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol. 1998;36:2950–6.PubMedGoogle Scholar
  93. 93.
    Tawara S, Ikeda F, Maki K, et al. In vitro activities of a new ­lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother. 2000;44:57–62.PubMedGoogle Scholar
  94. 94.
    Isham N, Ghannoum MA. Determination of MICs of aminocandin for Candida spp. and filamentous fungi. J Clin Microbiol. 2006;44:4342–4.PubMedGoogle Scholar
  95. 95.
    Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Monzon A, Buitrago MJ, Rodriguez-Tudela JL. Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. Antimicrob Agents Chemother. 2009;53:2192–5.PubMedGoogle Scholar
  96. 96.
    Lamaris GA, Lewis RE, Chamilos G, et al. Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae. J Infect Dis. 2008;198:186–92.PubMedGoogle Scholar
  97. 97.
    Lionakis MS, Lewis RE, Samonis G, Kontoyiannis DP. Pentamidine is active in vitro against Fusarium species. Antimicrob Agents Chemother. 2003;47:3252–9.PubMedGoogle Scholar
  98. 98.
    Li L, Wang Z, Li R, Luo S, Sun X. In vitro evaluation of combination antifungal activity against Fusarium species isolated from ocular tissues of keratomycosis patients. Am J Ophthalmol. 2008;146:724–8.PubMedGoogle Scholar
  99. 99.
    Ortoneda M, Capilla J, Javier Pastor F, Pujol I, Guarro J. In vitro interactions of licensed and novel antifungal drugs against Fusarium spp. Diagn Microbiol Infect Dis. 2004;48:69–71.PubMedGoogle Scholar
  100. 100.
    Arikan S, Lozano-Chiu M, Paetznick V, Rex JH. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother. 2002;46:245–7.PubMedGoogle Scholar
  101. 101.
    Stern GA. In vitro antibiotic synergism against ocular fungal isolates. Am J Ophthalmol. 1978;86:359–67.PubMedGoogle Scholar
  102. 102.
    Clancy CJ, Nguyen MH. The combination of amphotericin B and azithromycin as a potential new therapeutic approach to fusariosis. J Antimicrob Chemother. 1998;41:127–30.PubMedGoogle Scholar
  103. 103.
    Gorman SR, Magiorakos AP, Zimmerman SK, Craven DE. Fusarium oxysporum pneumonia in an immunocompetent host. South Med J. 2006;99:613–6.PubMedGoogle Scholar
  104. 104.
    Kontoyiannis DP, Bodey GP, Hanna H, et al. Outcome determinants of fusariosis in a tertiary care cancer center: the impact of neutrophil recovery. Leuk Lymphoma. 2004;45:139–41.PubMedGoogle Scholar
  105. 105.
    Nucci M, Anaissie EJ, Queiroz-Telles F, et al. Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer. 2003;98:315–9.PubMedGoogle Scholar
  106. 106.
    Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis. 1998;26:1383–96.PubMedGoogle Scholar
  107. 107.
    Cudillo L, Tendas A, Picardi A, et al. Successful treatment of disseminated fusariosis with high dose liposomal amphotericin-B in a patient with acute lymphoblastic leukemia. Ann Hematol. 2006;85:136–8.PubMedGoogle Scholar
  108. 108.
    Perfect JR. Treatment of non-Aspergillusmoulds in immunocompromised patients, with amphotericin B lipid complex. Clin Infect Dis. 2005;40 Suppl 6:S401–8.PubMedGoogle Scholar
  109. 109.
    Torres HA, Hachem RY, Chemaly RF, Kontoyiannis DP, Raad II. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis. 2005;5:775–85.PubMedGoogle Scholar
  110. 110.
    Consigny S, Dhedin N, Datry A, Choquet S, Leblond V, Chosidow O. Successsful voriconazole treatment of disseminated Fusarium infection in an immunocompromised patient. Clin Infect Dis. 2003;37:311–3.PubMedGoogle Scholar
  111. 111.
    Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis. 2003;36:1122–31.PubMedGoogle Scholar
  112. 112.
    Baden LR, Katz JT, Fishman JA, et al. Salvage therapy with voriconazole for invasive fungal infections in patients failing or intolerant to standard antifungal therapy. Transplantation. 2003;76:1632–7.PubMedGoogle Scholar
  113. 113.
    Cudillo L, Girmenia C, Santilli S, et al. Breakthrough fusariosis in a patient with acute lymphoblastic leukemia receiving voriconazole prophylaxis. Clin Infect Dis. 2005;40:1212–3.PubMedGoogle Scholar
  114. 114.
    Hachem R, Raad I, Afif C, al e. An open, non-comparative multicenter study to evaluate efficacy and safety of posaconazole (SCH 56592) in the treatment of invasive fungal infections refractory to or intolerant of standard therapy. In: Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; Toronto; 2000.Google Scholar
  115. 115.
    Raad II, Hachem RY, Herbrecht R, et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis. 2006;42:1398–403.PubMedGoogle Scholar
  116. 116.
    Alexander BD, Perfect JR, Daly JS, et al. Posaconazole as salvage therapy in patients with invasive fungal infections after solid organ transplant. Transplantation. 2008;86:791–6.PubMedGoogle Scholar
  117. 117.
    Ho DY, Lee JD, Rosso F, Montoya JG. Treating disseminated fusariosis: amphotericin B, voriconazole or both? Mycoses. 2007;50:227–31.PubMedGoogle Scholar
  118. 118.
    Durand-Joly I, Alfandari S, Benchikh Z, et al. Successful outcome of disseminated Fusarium infection with skin localization treated with voriconazole and amphotericin B-lipid complex in a patient with acute leukemia. J Clin Microbiol. 2003;41:4898–900.PubMedGoogle Scholar
  119. 119.
    Apostolidis J, Bouzani M, Platsouka E, et al. Resolution of fungemia due to Fusarium species in a patient with acute leukemia treated with caspofungin. Clin Infect Dis. 2003;36:1349–50.PubMedGoogle Scholar
  120. 120.
    Makowsky MJ, Warkentin DI, Savoie ML. Caspofungin and amphotericin B for disseminated Fusarium verticillioides in leukemia. Ann Pharmacother. 2005;39:1365–6.PubMedGoogle Scholar
  121. 121.
    Neuburger S, Massenkeil G, Seibold M, et al. Successful salvage treatment of disseminated cutaneous fusariosis with liposomal amphotericin B and terbinafine after allogeneic stem cell transplantation. Transpl Infect Dis. 2008;10:290–3.PubMedGoogle Scholar
  122. 122.
    Rothe A, Seibold M, Hoppe T, et al. Combination therapy of disseminated Fusarium oxysporum infection with terbinafine and amphotericin B. Ann Hematol. 2004;83:394–7.PubMedGoogle Scholar
  123. 123.
    Reuben A, Anaissie E, Nelson PE, et al. Antifungal susceptibility of 44 clinical isolates of Fusarium species determined by using a broth microdilution method. Antimicrob Agents Chemother. 1989;33:1647–9.PubMedGoogle Scholar
  124. 124.
    Hirose H, Terasaki H, Awaya S, Yasuma T. Treatment of fungal corneal ulcers with amphotericin B ointment. Am J Ophthalmol. 1997;124:836–8.PubMedGoogle Scholar
  125. 125.
    Sponsel WE, Graybill JR, Nevarez HL, Dang D. Ocular and systemic posaconazole(SCH-56592) treatment of invasive Fusarium solani keratitis and endophthalmitis. Br J Ophthalmol. 2002;86:829–30.PubMedGoogle Scholar
  126. 126.
    Rowsey JJ, Acers TE, Smith DL, Mohr JA, Newsom DL, Rodriguez J. Fusarium oxysporum endophthalmitis. Arch Ophthalmol. 1979;97:103–5.PubMedGoogle Scholar
  127. 127.
    Gabriele P, Hutchins RK. Fusarium endophthalmitis in an intravenous drug abuser. Am J Ophthalmol. 1996;122:119–21.PubMedGoogle Scholar
  128. 128.
    Glasgow BJ, Engstrom Jr RE, Holland GN, Kreiger AE, Wool MG. Bilateral endogenous Fusarium endophthalmitis associated with acquired immunodeficiency syndrome. Arch Ophthalmol. 1996;114:873–7.PubMedGoogle Scholar
  129. 129.
    Durand ML, Kim IK, D’Amico DJ, et al. Successful treatment of Fusarium endophthalmitis with voriconazole and Aspergillus endophthalmitis with voriconazole plus caspofungin. Am J Ophthalmol. 2005;140:552–4.PubMedGoogle Scholar
  130. 130.
    Restrepo A. Treatment of tropical mycoses. J Am Acad Dermatol. 1994;31:S91–102.PubMedGoogle Scholar
  131. 131.
    Barret JP, Ramzy PI, Heggers JP, Villareal C, Herndon DN, Desai MH. Topical nystatin powder in severe burns: a new treatment for angioinvasive fungal infections refractory to other topical and systemic agents. Burns. 1999;25:505–8.PubMedGoogle Scholar
  132. 132.
    Guzman-Cottrill JA, Zheng X, Chadwick EG. Fusarium solani endocarditis successfully treated with liposomal amphotericin B and voriconazole. Pediatr Infect Dis J. 2004;23:1059–61.PubMedGoogle Scholar
  133. 133.
    Gupta AK, Baran R, Summerbell RC. Fusarium infections of the skin. Curr Opin Infect Dis. 2000;13:121–8.PubMedGoogle Scholar
  134. 134.
    Dornbusch HJ, Buzina W, Summerbell RC, et al. Fusarium verticillioidesabscess of the nasal septum in an immunosuppressed child: case report and identification of the morphologically atypical ­fungal strain. J Clin Microbiol. 2005;43:1998–2001.PubMedGoogle Scholar
  135. 135.
    Farmaki E, Roilides E. Immunotherapy in patients with systemic mycoses: a promising adjunct. BioDrugs. 2001;15:207–14.PubMedGoogle Scholar
  136. 136.
    Rodriguez-Adrian LJ, Grazziutti ML, Rex JH, Anaissie EJ. The potential role of cytokine therapy for fungal infections in patients with cancer: is recovery from neutropenia all that is needed? Clin Infect Dis. 1998;26:1270–8.PubMedGoogle Scholar
  137. 137.
    Winn R, Maloukou A, Gil-Lamaignere C, et al. The Eurofung Network. Interferon-gamma and granulocyte-macrophage colony stimulating factor enhance hyphal damage of Aspergillus and Fusarium spp by human neutrophils.. In: Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago; 2001.Google Scholar
  138. 138.
    Gil-Lamaignere C, Winn RM, Simitsopoulou M, Maloukou A, Walsh TJ, Roilides E. Inteferon gamma and granulocyte-macrophage colony-stimulating factor augment the antifungal activity of human polymorphonuclear leukocytes against Scedosporium spp.: comparison with Aspergillus spp. Med Mycol. 2005;43:253–60.PubMedGoogle Scholar
  139. 139.
    Lewis R, Hogan H, Howell A, Safdar A. Progressive fusariosis: unpredictable posaconazole bioavailability, and feasibility of recombinant interferon-gamma plus granulocyte macrophage-colony stimulating factor for refractory disseminated infection. Leuk Lymphoma. 2008;49:163–5.PubMedGoogle Scholar
  140. 140.
    Cortez KJ, Roilides E, Quiroz-Telles F, et al. Infections caused by Scedosporium spp. Clin Microbiol Rev. 2008;21:157–97.PubMedGoogle Scholar
  141. 141.
    Gilgado F, Cano J, Gene J, Sutton DA, Guarro J. Molecular and phenotypic data supporting distinct species statuses for Scedosporium apiospermum and Pseudallescheria boydii and the proposed new species Scedosporium dehoogii. J Clin Microbiol. 2008;46:766–71.PubMedGoogle Scholar
  142. 142.
    Delhaes L, Harun A, Chen SC, et al. Molecular typing of Australian Scedosporium isolates showing genetic variability and numerous S. aurantiacum. Emerg Infect Dis. 2008;14:282–90.PubMedGoogle Scholar
  143. 143.
    Tadros TS, Workowski KA, Siegel RJ, Hunter S, Schwartz DA. Pathology of hyalohyphomycosis caused by Scedosporium apiospermum (Pseudallescheria boydii): an emerging mycosis. Hum Pathol. 1998;29:1266–72.PubMedGoogle Scholar
  144. 144.
    Rippon J. Pseudallescheriasis. In: Rippon JW, editor. Medical Mycology. 3rd ed. Philadelphia: W. B. Saunders Company; 1988. p. 651–80.Google Scholar
  145. 145.
    Malani AN, Kauffman CA. Changing epidemiology of rare mould infections: Implications for therapy. Drugs. 2007;67:1803–12.PubMedGoogle Scholar
  146. 146.
    Francis P, Walsh TJ. Approaches to management of fungal infections in cancer patients. Oncology (Williston Park). 1992;6:133–44. discussion 44, 47-8.Google Scholar
  147. 147.
    Corbel MJ, Eades SM. The relative susceptibility of New Zealand black and CBA mice to infection with opportunistic fungal pathogens. Sabouraudia. 1976;14:17–32.PubMedGoogle Scholar
  148. 148.
    Travis LB, Roberts GD, Wilson WR. Clinical significance of Pseudallescheria boydii: a review of 10 years’ experience. Mayo Clin Proc. 1985;60:531–7.PubMedGoogle Scholar
  149. 149.
    Kiratli H, Uzun O, Kiraz N, Eldem B. Scedosporium apiospermum chorioretinitis. Acta Ophthalmol Scand. 2001;79:540–2.PubMedGoogle Scholar
  150. 150.
    Wu Z, Ying H, Yiu S, Irvine J, Smith R. Fungal keratitis caused by Scedosporium apiospermum: report of two cases and review of treatment. Cornea. 2002;21:519–23.PubMedGoogle Scholar
  151. 151.
    Mesfin FB, Tobin E, Adamo MA, Dirisio D. Fungal vertebral osteomyelitis due to Scedosporium apiospermum after near-drowning. J Neurosurg Spine. 2008;9:58–61.PubMedGoogle Scholar
  152. 152.
    Garzoni C, Emonet S, Legout L, et al. Atypical infections in tsunami survivors. Emerg Infect Dis. 2005;11:1591–3.PubMedGoogle Scholar
  153. 153.
    Kiraz N, Gulbas Z, Akgun Y, Uzun O. Lymphadenitis caused by Scedosporium apiospermum in an immunocompetent patient. Clin Infect Dis. 2001;32:E59–61.PubMedGoogle Scholar
  154. 154.
    Patterson TF, Andriole VT, Zervos MJ, Therasse D, Kauffman CA. The epidemiology of pseudallescheriasis complicating transplantation: nosocomial and community-acquired infection. Mycoses. 1990;33:297–302.PubMedGoogle Scholar
  155. 155.
    Armin AR, Reddy VB, Orfei E. Fungal endocarditis caused by Pseudallescheria (Petriellidium) boydii in an intravenous drug abuser. Tex Heart Inst J. 1987;14:321–4.PubMedGoogle Scholar
  156. 156.
    Patterson JE. Epidemiology of fungal infections in solid organ transplant patients. Transpl Infect Dis. 1999;1:229–36.PubMedGoogle Scholar
  157. 157.
    Nesky MA, McDougal EC, Peacock Jr JE. Pseudallescheria boydii brain abscess successfully treated with voriconazole and surgical drainage: case report and literature review of central nervous system pseudallescheriasis. Clin Infect Dis. 2000;31:673–7.PubMedGoogle Scholar
  158. 158.
    Husain S, Munoz P, Forrest G, et al. Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis. 2005;40:89–99.PubMedGoogle Scholar
  159. 159.
    Raj R, Frost AE. Scedosporium apiospermum fungemia in a lung transplant recipient. Chest. 2002;121:1714–6.PubMedGoogle Scholar
  160. 160.
    Jabado N, Casanova JL, Haddad E, et al. Invasive pulmonary infection due to Scedosporium apiospermum in two children with chronic granulomatous disease. Clin Infect Dis. 1998;27:1437–41.PubMedGoogle Scholar
  161. 161.
    Cimon B, Carrere J, Vinatier JF, Chazalette JP, Chabasse D, Bouchara JP. Clinical significance of Scedosporium apiospermum in patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis. 2000;19:53–6.PubMedGoogle Scholar
  162. 162.
    Castelli MV, Buitrago MJ, Bernal-Martinez L, Gomez-Lopez A, Rodriguez-Tudela JL, Cuenca-Estrella M. Development and validation of a quantitative PCR assay for diagnosis of scedosporiosis. J Clin Microbiol. 2008;46:3412–6.PubMedGoogle Scholar
  163. 163.
    Meletiadis J, Meis JF, Mouton JW, Rodriquez-Tudela JL, Donnelly JP, Verweij PE. In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob Agents Chemother. 2002;46:62–8.PubMedGoogle Scholar
  164. 164.
    Troke P, Aguirrebengoa K, Arteaga C, et al. Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob Agents Chemother. 2008;52:1743–50.PubMedGoogle Scholar
  165. 165.
    Gonzalez GM, Tijerina R, Najvar LK, et al. Activity of posaconazole against Pseudallescheria boydii: in vitro and in vivo assays. Antimicrob Agents Chemother. 2003;47:1436–8.PubMedGoogle Scholar
  166. 166.
    Cuenca-Estrella M, Alastruey-Izquierdo A, Alcazar-Fuoli L, et al. In vitro activities of 35 double combinations of antifungal agents against Scedosporium apiospermum and Scedosporium prolificans. Antimicrob Agents Chemother. 2008;52:1136–9.PubMedGoogle Scholar
  167. 167.
    Heyn K, Tredup A, Salvenmoser S, Muller FM. Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani. Antimicrob Agents Chemother. 2005;49:5157–9.PubMedGoogle Scholar
  168. 168.
    Yustes C, Guarro J. In vitro synergistic interaction between amphotericin B and micafungin against Scedosporium spp. Antimicrob Agents Chemother. 2005;49:3498–500.PubMedGoogle Scholar
  169. 169.
    Caira M, Girmenia C, Valentini CG, et al. Scedosporiosis in patients with acute leukemia: a retrospective multicenter report. Haematologica. 2008;93:104–10.PubMedGoogle Scholar
  170. 170.
    Katragkou A, Dotis J, Kotsiou M, Tamiolaki M, Roilides E. Scedosporium apiospermum infection after near-drowning. Mycoses. 2007;50:412–21.PubMedGoogle Scholar
  171. 171.
    Lamaris GA, Chamilos G, Lewis RE, Safdar A, Raad II, Kontoyiannis DP. Scedosporium infection in a tertiary care cancer center: a review of 25 cases from 1989–2006. Clin Infect Dis. 2006;43:1580–4.PubMedGoogle Scholar
  172. 172.
    Nochez Y, Arsene S, Le Guellec C, et al. Unusual pharmacokinetics of intravitreal and systemic voriconazole in a patient with Scedosporium apiospermum endophthalmitis. J Ocul Pharmacol Ther. 2008;24:87–90.PubMedGoogle Scholar
  173. 173.
    Mellinghoff IK, Winston DJ, Mukwaya G, Schiller GJ. Treatment of Scedosporium apiospermum brain abscesses with posaconazole. Clin Infect Dis. 2002;34:1648–50.PubMedGoogle Scholar
  174. 174.
    Abzug MJ, Walsh TJ. Interferon-gamma and colony-stimulating ­factors as adjuvant therapy for refractory fungal infections in ­children. Pediatr Infect Dis J. 2004;23:769–73.PubMedGoogle Scholar
  175. 175.
    Cooley L, Spelman D, Thursky K, Slavin M. Infection with Scedosporium apiospermum and S. prolificans, Australia. Emerg Infect Dis. 2007;13:1170–7.PubMedGoogle Scholar
  176. 176.
    Perfect JR, Schell WA. The new fungal opportunists are coming. Clin Infect Dis. 1996;22 Suppl 2:S112–8.PubMedGoogle Scholar
  177. 177.
    Roilides E, Simitsopoulou M, Katragkou A, Walsh TJ. Host immune response against Scedosporium species. Med Mycol. 2009;47:433–40.PubMedGoogle Scholar
  178. 178.
    Ortoneda M, Capilla J, Pujol I, et al. Liposomal amphotericin B and granulocyte colony-stimulating factor therapy in a murine model of invasive infection by Scedosporium prolificans. J Antimicrob Chemother. 2002;49:525–9.PubMedGoogle Scholar
  179. 179.
    Berenguer J, Rodriguez-Tudela JL, Richard C, et al. Deep infections caused by Scedosporium prolificans. A report on 16 cases in Spain and a review of the literature. Scedosporium prolificans Spanish Study Group. Medicine (Baltimore). 1997;76:256–65.Google Scholar
  180. 180.
    Rodriguez-Tudela JL, Berenguer J, Guarro J, et al. Epidemiology and outcome of Scedosporium prolificans infection, a review of 162 cases. Med Mycol. 2009;47:359–70.PubMedGoogle Scholar
  181. 181.
    Carreter de Granda ME, Richard C, Conde E, et al. Endocarditis caused by Scedosporium prolificans after autologous peripheral blood stem cell transplantation. Eur J Clin Microbiol Infect Dis. 2001;20:215–7.PubMedGoogle Scholar
  182. 182.
    Lopez L, Gaztelurrutia L, Cuenca-Estrella M, et al. Infection and colonization by Scedosporium prolificans. Enferm Infecc Microbiol Clín. 2001;19:308–13.PubMedGoogle Scholar
  183. 183.
    Salkin IF, McGinnis MR, Dykstra MJ, Rinaldi MG. Scedosporium inflatum, an emerging pathogen. J Clin Microbiol. 1988;26:498–503.PubMedGoogle Scholar
  184. 184.
    Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Buitrago MJ, Monzon A, Rodriguez-Tudela JL. Head-to-head comparison of the activities of currently available antifungal agents against 3, 378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother. 2006;50:917–21.PubMedGoogle Scholar
  185. 185.
    Del Poeta M, Schell WA, Perfect JR. In vitro antifungal activity of pneumocandin L-743, 872 against a variety of clinically important molds. Antimicrob Agents Chemother. 1997;41:1835–6.PubMedGoogle Scholar
  186. 186.
    McGinnis MR, Pasarell L, Sutton DA, Fothergill AW, Cooper Jr CR, Rinaldi MG. In vitro activity of voriconazole against selected fungi. Med Mycol. 1998;36:239–42.PubMedGoogle Scholar
  187. 187.
    Carrillo AJ, Guarro J. In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob Agents Chemother. 2001;45:2151–3.PubMedGoogle Scholar
  188. 188.
    Afeltra J, Dannaoui E, Meis JF, Rodriguez-Tudela JL, Verweij PE. In vitro synergistic interaction between amphotericin B and pentamidine against Scedosporium prolificans. Antimicrob Agents Chemother. 2002;46:3323–6.PubMedGoogle Scholar
  189. 189.
    Meletiadis J, Mouton JW, Rodriguez-Tudela JL, Meis JF, Verweij PE. In vitro interaction of terbinafine with itraconazole against clinical isolates of Scedosporium prolificans. Antimicrob Agents Chemother. 2000;44:470–2.PubMedGoogle Scholar
  190. 190.
    Meletiadis J, Mouton JW, Meis JF, Verweij PE. In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob Agents Chemother. 2003;47:106–17.PubMedGoogle Scholar
  191. 191.
    Rodriguez MM, Calvo E, Serena C, Marine M, Pastor FJ, Guarro J. Effects of double and triple combinations of antifungal drugs in a murine model of disseminated infection by Scedosporium prolificans. Antimicrob Agents Chemother. 2009;53:2153–5.PubMedGoogle Scholar
  192. 192.
    Walsh TJ, Lutsar I, Driscoll T, et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J. 2002;21:240–8.PubMedGoogle Scholar
  193. 193.
    Tong SY, Peleg AY, Yoong J, Handke R, Szer J, Slavin M. Breakthrough Scedosporium prolificans infection while receiving voriconazole prophylaxis in an allogeneic stem cell transplant recipient. Transpl Infect Dis. 2007;9:241–3.PubMedGoogle Scholar
  194. 194.
    Ananda-Rajah MR, Grigg A, Slavin MA. Breakthrough ­disseminated Scedosporium prolificans infection in a patient with relapsed leukaemia on prolonged voriconazole followed by posaconazole prophylaxis. Mycopathologia. 2008;166:83–6.PubMedGoogle Scholar
  195. 195.
    Howden BP, Slavin MA, Schwarer AP, Mijch AM. Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine. Eur J Clin Microbiol Infect Dis. 2003;22:111–3.PubMedGoogle Scholar
  196. 196.
    Li JY, Yong TY, Grove DI, Coates PT. Successful control of Scedosporium prolificans septic arthritis and probable osteomyelitis without radical surgery in a long-term renal transplant recipient. Transpl Infect Dis. 2008;10:63–5.PubMedGoogle Scholar
  197. 197.
    Steinbach WJ, Schell WA, Miller JL, Perfect JR. Scedosporium prolificans osteomyelitis in an immunocompetent child treated with voriconazole and caspofungin, as well as locally applied polyhexamethylene biguanide. J Clin Microbiol. 2003;41:3981–5.PubMedGoogle Scholar
  198. 198.
    Kesson AM, Bellemore MC, O’Mara TJ, Ellis DH, Sorrell TC. Scedosporium prolificans osteomyelitis in an immunocompetent child treated with a novel agent, hexadecylphospocholine (miltefosine), in combination with terbinafine and voriconazole: a case report. Clin Infect Dis. 2009;48:1257–61.PubMedGoogle Scholar
  199. 199.
    Guarro J, Gams W, Pujol I, Gene J. Acremonium species: new emerging fungal opportunists–in vitro antifungal susceptibilities and review. Clin Infect Dis. 1997;25:1222–9.PubMedGoogle Scholar
  200. 200.
    Fridkin SK, Kremer FB, Bland LA, Padhye A, McNeil MM, Jarvis WR. Acremonium kiliense endophthalmitis that occurred after cataract extraction in an ambulatory surgical center and was traced to an environmental reservoir. Clin Infect Dis. 1996;22:222–7.PubMedGoogle Scholar
  201. 201.
    Pastorino AC, Menezes UP, Marques HH, et al. Acremonium kiliense infection in a child with chronic granulomatous disease. Braz J Infect Dis. 2005;9:529–34.PubMedGoogle Scholar
  202. 202.
    Schell WA, Perfect JR. Fatal, disseminated Acremonium strictum infection in a neutropenic host. J Clin Microbiol. 1996;34:1333–6.PubMedGoogle Scholar
  203. 203.
    Anadolu R, Hilmioglu S, Oskay T, Boyvat A, Peksari Y, Gurgey E. Indolent Acremonium strictum infection in an immunocompetent patient. Int J Dermatol. 2001;40:451–3.PubMedGoogle Scholar
  204. 204.
    Keynan Y, Sprecher H, Weber G. Acremonium vertebral osteomyelitis: molecular diagnosis and response to voriconazole. Clin Infect Dis. 2007;45:e5–6.PubMedGoogle Scholar
  205. 205.
    Roilides E, Bibashi E, Acritidou E, et al. Acremonium fungemia in two immunocompromised children. Pediatr Infect Dis J. 1995;14:548–50.PubMedGoogle Scholar
  206. 206.
    Fincher RM, Fisher JF, Lovell RD, Newman CL, Espinel-Ingroff A, Shadomy HJ. Infection due to the fungus Acremonium (cephalosporium). Medicine (Baltimore). 1991;70:398–409.Google Scholar
  207. 207.
    Chang YH, Huang LM, Hsueh PR, et al. Acremonium pyomyositis in a pediatric patient with acute leukemia. Pediatr Blood Cancer. 2005;44:521–4.PubMedGoogle Scholar
  208. 208.
    Sener AG, Yucesoy M, Senturkun S, Afsar I, Yurtsever SG, Turk M. A case of Acremonium strictum peritonitis. Med Mycol. 2008;46:495–7.PubMedGoogle Scholar
  209. 209.
    Yalaz M, Hilmioglu S, Metin D, et al. Fatal disseminated Acremonium strictum infection in a preterm newborn: a very rare cause of neonatal septicaemia. J Med Microbiol. 2003;52:835–7.PubMedGoogle Scholar
  210. 210.
    Yamazaki R, Mori T, Aisa Y, et al. Systemic infection due to Acremonium after allogeneic peripheral blood stem cell transplantation. Intern Med. 2006;45:989–90.PubMedGoogle Scholar
  211. 211.
    Miyakis S, Velegraki A, Delikou S, et al. Invasive Acremonium strictum infection in a bone marrow transplant recipient. Pediatr Infect Dis J. 2006;25:273–5.PubMedGoogle Scholar
  212. 212.
    Weissgold DJ, Maguire AM, Brucker AJ. Management of postoperative Acremonium endophthalmitis. Ophthalmology. 1996;103:749–56.PubMedGoogle Scholar
  213. 213.
    Filipello Marchisio V, Fusconi A. Morphological evidence for keratinolytic activity of Scopulariopsis spp. isolates from nail lesions and the air. Med Mycol. 2001;39:287–94.PubMedGoogle Scholar
  214. 214.
    Steinbach WJ, Schell WA, Miller JL, Perfect JR, Martin PL. Fatal Scopulariopsis brevicaulis infection in a paediatric stem-cell transplant patient treated with voriconazole and caspofungin and a review of Scopulariopsis infections in immunocompromised patients. J Infect. 2004;48:112–6.PubMedGoogle Scholar
  215. 215.
    Shankar EM, Vignesh R, Barton RC, et al. Hydrothorax in association with Scopulariopsis brumptii in an AIDS patient in Chennai, India. Trans R Soc Trop Med Hyg. 2007;101:1270–2.PubMedGoogle Scholar
  216. 216.
    Aydin S, Ertugrul B, Gultekin B, Uyar G, Kir E. Treatment of two postoperative endophthalmitis cases due to Aspergillus flavus and Scopulariopsis spp. with local and systemic antifungal therapy. BMC Infect Dis. 2007;7:87.PubMedGoogle Scholar
  217. 217.
    Vollmer T, Stormer M, Kleesiek K, Dreier J. Evaluation of novel broad-range real-time PCR assay for rapid detection of human pathogenic fungi in various clinical specimens. J Clin Microbiol. 2008;46:1919–26.PubMedGoogle Scholar
  218. 218.
    Isidro AM, Amorosa V, Stopyra GA, Rutenberg HL, Pentz WH, Bridges CR. Fungal prosthetic mitral valve endocarditis caused by Scopulariopsisspecies: case report and review of the literature. J Thorac Cardiovasc Surg. 2006;131:1181–3.PubMedGoogle Scholar
  219. 219.
    Sellier P, Monsuez JJ, Lacroix C, et al. Recurrent subcutaneous infection due to Scopulariopsis brevicaulis in a liver transplant recipient. Clin Infect Dis. 2000;30:820–3.PubMedGoogle Scholar
  220. 220.
    Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Buitrago MJ, Monzon A, Rodriguez-Tudela JL. Scopulariopsis brevicaulis, a fungal pathogen resistant to broad-spectrum antifungal agents. Antimicrob Agents Chemother. 2003;47:2339–41.PubMedGoogle Scholar
  221. 221.
    Carrillo-Munoz AJ, Giusiano G, Guarro J, et al. In vitro activity of voriconazole against dermatophytes, Scopulariopsis brevicaulis and other opportunistic fungi as agents of onychomycosis. Int J Antimicrob Agents. 2007;30:157–61.PubMedGoogle Scholar
  222. 222.
    Cuenca-Estrella M, Gomez-Lopez A, Buitrago MJ, Mellado E, Garcia-Effron G, Rodriguez-Tudela JL. In vitro activities of 10 combinations of antifungal agents against the multiresistant pathogen Scopulariopsis brevicaulis. Antimicrob Agents Chemother. 2006;50:2248–50.PubMedGoogle Scholar
  223. 223.
    Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Garcia-Effron G, Monzon A, Rodriguez-Tudela JL. In vitro activity of ravuconazole against 923 clinical isolates of nondermatophyte filamentous fungi. Antimicrob Agents Chemother. 2005;49:5136–8.PubMedGoogle Scholar
  224. 224.
    Wagner D, Sander A, Bertz H, Finke J, Kern WV. Breakthrough invasive infection due to Debaryomyces hansenii (teleomorph Candida famata) and Scopulariopsis brevicaulis in a stem cell transplant patient receiving liposomal amphotericin B and caspofungin for suspected aspergillosis. Infection. 2005;33:397–400.PubMedGoogle Scholar
  225. 225.
    Patel R, Gustaferro CA, Krom RA, Wiesner RH, Roberts GD, Paya CV. Phaeohyphomycosis due to Scopulariopsis brumptii in a liver transplant recipient. Clin Infect Dis. 1994;19:198–200.PubMedGoogle Scholar
  226. 226.
    Kriesel JD, Adderson EE, Gooch 3rd WM, Pavia AT. Invasive sinonasal disease due to Scopulariopsis candida: case report and review of scopulariopsosis. Clin Infect Dis. 1994;19:317–9.PubMedGoogle Scholar
  227. 227.
    Lovell RD, Moll M, Allen J, Cicci LG. Disseminated Paecilomyces lilacinusinfection in a patient with AIDS. AIDS Read. 2002;12:212–3. 8, 21.PubMedGoogle Scholar
  228. 228.
    Safdar A. Progressive cutaneous hyalohyphomycosis due to Paecilomyces lilacinus: rapid response to treatment with caspofungin and itraconazole. Clin Infect Dis. 2002;34:1415–7.PubMedGoogle Scholar
  229. 229.
    Van Schooneveld T, Freifeld A, Lesiak B, Kalil A, Sutton DA, Iwen PC. Paecilomyces lilacinus infection in a liver transplant patient: case report and review of the literature. Transpl Infect Dis. 2008;10:117–22.PubMedGoogle Scholar
  230. 230.
    Gutierrez-Rodero F, Moragon M, Ortiz de laTabla V, Mayol MJ, Martin C. Cutaneous hyalohyphomycosis caused by Paecilomyces lilacinus in an immunocompetent host successfully treated with itraconazole: case report and review. Eur J Clin Microbiol Infect Dis. 1999;18:814–8.PubMedGoogle Scholar
  231. 231.
    Clark NM. Paecilomyces lilacinus infection in a heart transplant recipient and successful treatment with terbinafine. Clin Infect Dis. 1999;28:1169–70.PubMedGoogle Scholar
  232. 232.
    Orth B, Frei R, Itin PH, et al. Outbreak of invasive mycoses caused by Paecilomyces lilacinus from a contaminated skin lotion. Ann Intern Med. 1996;125:799–806.PubMedGoogle Scholar
  233. 233.
    Pastor FJ, Guarro J. Clinical manifestations, treatment and outcome of Paecilomyces lilacinus infections. Clin Microbiol Infect. 2006;12:948–60.PubMedGoogle Scholar
  234. 234.
    Wessolossky M, Haran JP, Bagchi K. Paecilomyces lilacinusolecranon bursitis in an immunocompromised host: case report and review. Diagn Microbiol Infect Dis. 2008;61:354–7.PubMedGoogle Scholar
  235. 235.
    Shing MM, Ip M, Li CK, Chik KW, Yuen PM. Paecilomyces variotifungemia in a bone marrow transplant patient. Bone Marrow Transplant. 1996;17:281–3.PubMedGoogle Scholar
  236. 236.
    Lionakis MS, Bodey GP, Tarrand JJ, Raad II, Kontoyiannis DP. The significance of blood cultures positive for emerging saprophytic moulds in cancer patients. Clin Microbiol Infect. 2004;10:922–5.PubMedGoogle Scholar
  237. 237.
    Aguilar C, Pujol I, Sala J, Guarro J. Antifungal susceptibilities of Paecilomyces species. Antimicrob Agents Chemother. 1998;42:1601–4.PubMedGoogle Scholar
  238. 238.
    Gottlieb T, Atkins BL. Case report. Successful treatment of cutaneous Paecilomyces lilacinus infection with oral itraconazole in an immune competent host. Mycoses. 2001;44:513–5.PubMedGoogle Scholar
  239. 239.
    Das A, MacLaughlin EF, Ross LA, et al. Paecilomyces variotii in a pediatric patient with lung transplantation. Pediatr Transplant. 2000;4:328–32.PubMedGoogle Scholar
  240. 240.
    Ortoneda M, Capilla J, Pastor FJ, et al. In vitro interactions of approved and novel drugs against Paecilomyces spp. Antimicrob Agents Chemother. 2004;48:2727–9.PubMedGoogle Scholar
  241. 241.
    Chan-Tack KM, Thio CL, Miller NS, Karp CL, Ho C, Merz WG. Paecilomyces lilacinus fungemia in an adult bone marrow transplant recipient. Med Mycol. 1999;37:57–60.PubMedGoogle Scholar
  242. 242.
    Hilmarsdottir I, Thorsteinsson SB, Asmundsson P, Bodvarsson M, Arnadottir M. Cutaneous infection caused by Paecilomyces lilacinus in a renal transplant patient: treatment with voriconazole. Scand J Infect Dis. 2000;32:331–2.PubMedGoogle Scholar
  243. 243.
    Mullane K, Toor AA, Kalnicky C, Rodriguez T, Klein J, Stiff P. Posaconazole salvage therapy allows successful allogeneic hematopoietic stem cell transplantation in patients with refractory invasive mold infections. Transpl Infect Dis. 2007;9:89–96.PubMedGoogle Scholar
  244. 244.
    Wang SM, Shieh CC, Liu CC. Successful treatment of Paecilomyces variotii splenic abscesses: a rare complication in a previously unrecognized chronic granulomatous disease child. Diagn Microbiol Infect Dis. 2005;53:149–52.PubMedGoogle Scholar
  245. 245.
    Ford JG, Agee S, Greenhaw ST. Successful medical treatment of a case of Paecilomyces lilacinus keratitis. Cornea. 2008;27:1077–9.PubMedGoogle Scholar
  246. 246.
    Stillwell WT, Rubin BD, Axelrod JL. Chrysosporium, a new causative agent in osteomyelitis. A case report. Clin Orthop Relat Res 1984:184:190–2.Google Scholar
  247. 247.
    Levy FE, Larson JT, George E, Maisel RH. Invasive Chrysosporiuminfection of the nose and paranasal sinuses in an immunocompromised host. Otolaryngol Head Neck Surg. 1991;104:384–8.PubMedGoogle Scholar
  248. 248.
    Warwick A, Ferrieri P, Burke B, Blazar BR. Presumptive invasive Chrysosporium infection in a bone marrow transplant recipient. Bone Marrow Transplant. 1991;8:319–22.PubMedGoogle Scholar
  249. 249.
    Munoz FM, Demmler GJ, Travis WR, Ogden AK, Rossmann SN, Rinaldi MG. Trichoderma longibrachiatum infection in a pediatric­ patient with aplastic anemia. J Clin Microbiol. 1997;35:499–503.PubMedGoogle Scholar
  250. 250.
    Roilides E, Sigler L, Bibashi E, Katsifa H, Flaris N, Panteliadis C. Disseminated infection due to Chrysosporium zonatum in a patient with chronic granulomatous disease and review of non-Aspergillus fungal infections in patients with this disease. J Clin Microbiol. 1999;37:18–25.PubMedGoogle Scholar
  251. 251.
    Wagoner MD, Badr IA, Hidayat AA. Chrysosporium parvum ­keratomycosis. Cornea. 1999;18:616–20.PubMedGoogle Scholar
  252. 252.
    Lagrange-Xelot M, Schlemmer F, Gallien S, Lacroix C, Molina JM. Trichoderma fungaemia in a neutropenic patient with pulmonary cancer and human immunodeficiency virus infection. Clin Microbiol Infect. 2008;14:1190–2.PubMedGoogle Scholar
  253. 253.
    Kviliute R, Paskevicius A, Gulbinovic J, Stulpinas R, Griskevicius L. Nonfatal Trichoderma citrinoviride pneumonia in an acute myeloid leukemia patient. Ann Hematol. 2008;87:501–2.PubMedGoogle Scholar
  254. 254.
    Maran AG, Kwong K, Milne LJ, Lamb D. Frontal sinusitis caused by Myriodontium keratinophilum. Br Med J (Clin Res Ed). 1985;290:207.Google Scholar
  255. 255.
    Ahmad S, Johnson RJ, Hillier S, Shelton WR, Rinaldi MG. Fungal peritonitis caused by Lecythophora mutabilis. J Clin Microbiol. 1985;22:182–6.PubMedGoogle Scholar
  256. 256.
    Jacobs F, Byl B, Bourgeois N, et al. Trichoderma viride infection in a liver transplant recipient. Mycoses. 1992;35:301–3.PubMedGoogle Scholar
  257. 257.
    Farina C, Vailati F, Manisco A, Goglio A. Fungaemia survey: a 10-year experience in Bergamo, Italy. Mycoses. 1999;42:543–8.PubMedGoogle Scholar
  258. 258.
    Chin-Hong PV, Sutton DA, Roemer M, Jacobson MA, Aberg JA. Invasive fungal sinusitis and meningitis due to Arthrographis kalrae in a patient with AIDS. J Clin Microbiol. 2001;39:804–7.PubMedGoogle Scholar
  259. 259.
    Henke MO, De Hoog GS, Gross U, Zimmermann G, Kraemer D, Weig M. Human deep tissue infection with an entomopathogenic Beauveria species. J Clin Microbiol. 2002;40:2698–702.PubMedGoogle Scholar
  260. 260.
    Suh MK, Lim JW, Lee YH, et al. Subcutaneous hyalohyphomycosis due to Cephalotheca foveolata in an immunocompetent host. Br J Dermatol. 2006;154:1184–9.PubMedGoogle Scholar
  261. 261.
    Chouaki T, Lavarde V, Lachaud L, Raccurt CP, Hennequin C. Invasive infections due to Trichoderma species: report of 2 cases, findings of in vitro susceptibility testing, and review of the literature. Clin Infect Dis. 2002;35:1360–7.PubMedGoogle Scholar
  262. 262.
    Loeppky CB, Sprouse RF, Carlson JV, Everett ED. Trichoderma viride peritonitis. South Med J. 1983;76:798–9.PubMedGoogle Scholar
  263. 263.
    Furukawa H, Kusne S, Sutton DA, et al. Acute invasive sinusitis due to Trichoderma longibrachiatum in a liver and small bowel transplant recipient. Clin Infect Dis. 1998;26:487–9.PubMedGoogle Scholar
  264. 264.
    Richter S, Cormican MG, Pfaller MA, et al. Fatal disseminated Trichoderma longibrachiatum infection in an adult bone marrow transplant patient: species identification and review of the literature. J Clin Microbiol. 1999;37:1154–60.PubMedGoogle Scholar
  265. 265.
    Hennequin C, Chouaki T, Pichon JC, Strunski V, Raccurt C. Otitis externa due to Trichoderma longibrachiatum. Eur J Clin Microbiol Infect Dis. 2000;19:641–2.PubMedGoogle Scholar
  266. 266.
    Kratzer C, Tobudic S, Schmoll M, Graninger W, Georgopoulos A. In vitro activity and synergism of amphotericin B, azoles and cationic antimicrobials against the emerging ­pathogen Trichoderma spp. J Antimicrob Chemother. 2006;58:1058–61.PubMedGoogle Scholar
  267. 267.
    De Miguel D, Gomez P, Gonzalez R, et al. Nonfatal pulmonary Trichoderma viride infection in an adult patient with acute myeloid leukemia: report of one case and review of the literature. Diagn Microbiol Infect Dis. 2005;53:33–7.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Department of Internal MedicineThe University of Texas, MD Anderson Cancer CenterHoustonUSA

Personalised recommendations